It Takes “Guts” to Cause Joint Inflammation: Role of Innate-Like T Cells

Céline Mortier1,2†, Srinath Govindarajan1,2†, Koen Venken1,2‡ and Dirk Elewaut1,2*‡

1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Unit for Molecular Immunology and Inflammation, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium

Innate-like T cells such as invariant natural killer T (iNKT) cells and mucosal-associated T (MAIT) cells, characterized by a semi-invariant T cell receptor and restriction toward MHC-like molecules (CD1 and MR1 respectively), are a unique unconventional immune subset acting at the interface of innate and adaptive immunity. Highly represented at barrier sites and capable of rapidly producing substantial amounts of cytokines, they serve a pivotal role as first-line responders against microbial infections. In contrast, it was demonstrated that innate-like T cells can be skewed toward a predominant pro-inflammatory state and are consequently involved in a number of autoimmune and inflammatory diseases like inflammatory bowel diseases and rheumatic disorders, such as spondyloarthritis (SpA) and rheumatoid arthritis. Interestingly, there is link between gut and joint disease as they often co-incide and share certain aspects of the pathogenesis such as established genetic risk factors, a critical role for pro-inflammatory cytokines, such as TNF-α, IL-23, and IL-17 and therapeutic susceptibility. In this regard dysregulated IL-23/IL-17 responses appear to be crucial in both debilitating pathologies and innate-like T cells likely act as key player. In this review, we will explore the remarkable features of iNKT cells and MAIT cells, and discuss their contribution to immunity and combined gut–joint disease.

Keywords: innate-like T cells, invariant natural killer T cells, mucosal-associated invariant T cells, CD1, MR1, rheumatic diseases, inflammatory bowel disease, gut–joint axis

INTRODUCTION

Over the past decades, innate-like T cells have gained increasing attention given their unique biology and potential involvement in multiple immune and inflammatory diseases. Those cells, with overlapping features of both the innate and adaptive immune system, are characterized by an antigen-specific semi-invariant T cell receptor (TCR) with restricted V(D)J rearrangement. Innate-like T cells are able to rapidly produce cytokines, which makes them an ideal first-line defense against microbial infections (1). However, it has become clear that these cells show functional plasticity and can be skewed toward a more pro-inflammatory state (2). Two members of this unconventional T cell population are invariant natural killer T (iNKT) cells and mucosal-associated invariant T (MAIT) cells. Both cell types have the unique feature of recognizing atypical non-peptide antigens presented by highly conserved MHC-related molecules, respectively CD1 and MR1. iNKT cells respond to glycolipid molecules, whereas MAIT cells can be activated by vitamin B2 (riboflavin) metabolites, which are intermediates from bacterial and yeast biosynthetic pathways (3). Gamma
Furthermore, there is extensive evidence from in vivo phisms in the IL23R gene associated with both SpA and IBD (19). Pathogenesis of SpA (18). GWAS studies have revealed polymorphisms in the IL-23/IL-17 immune axis has manifested as a major player in the inflammatory cytokines like IL-17. Over the years, the interleukin significantly differ in their response toward inhibition of other key factors to anti-tumor necrosis factor (TNF)-α trials. Interestingly, SpA, RA, and IBD share clinical responsive-ness to anti-IL-17 treatment was not effective in patients with RA or IBD from genome-wide association studies (GWAS) and anti-cytokine therapy but sig-2 ontrary to conventional T cells which detect self or foreign peptide antigen–MHC complexes, iNKT cells recognize only glycolipid antigens bound to CD1d, a MHC class I-like glycoprotein (30). Currently, identified antigens are predominantly of non-mammalian nature, with α-galactosylceramide (α-GalCer) as the most potent and best studied example. However, also microbial derived (31) and endogenous ligands have been described (28, 32, 33). Of note, the human genome encodes five CD1d genes (CD1a, b, c, d, and e) whereas only CD1d is expressed in mice, and human CD1a, b, and c restricted T cells have been described too (34).

A hallmark of iNKT cell biology is the ability to secrete large amounts of cytokines and chemokines upon TCR recognition of lipid antigen–CD1 complexes or via indirect (TCR independent, mainly cytokine driven) stimulation, hereby acting as a "bridge" between innate and adaptive immune responses (35, 36). In analogy to classification of conventional T cells based on their cytokine production, iNKT cells can be subdivided in NKT1, NKT2, and NKT17 cells (37). Each of these subsets expresses distinct transcription factors which correlate with their capacity to secrete specific cytokines. NKT1 cells are T box transcription factor TBX21 (T-bet) positive and primarily secrete interferon (IFN)-γ, NKT2 cells express high levels of GATA-binding protein 3 (GATA3) and promyelocytic leukemia zinc finger protein (PLZF), and produce IL-4 and IL-13, and NKT17 cells express RORγt next to intermediate levels of PLZF and produce IL-17 as signature cytokine (38–40). All these subsets acquire their functional capacity during the development in the thymus and are distributed to the peripheral organs in a tissue-specific manner (41). However, there are also reports suggesting that peripheral iNKT cells are able to further functionally differentiate under inflammatory conditions (42, 43). In addition, it is also clear that iNKT cells experience further

**iNKT CELLS**

**Biology and Localization**

Invariant natural killer T cells are CD1d-restricted T cells which express a semi-invariant TCR consisting of an invariant α chain [in particular, the variable (V) and joining (J) segments Vα14–Jα18 in mice and Vα24–Jα18 in humans], combined with a restricted β chain repertoire, usually Vβ2, Vβ7, or Vβ8.2 in mice and Vβ11 in humans (28, 29). Identification of these cells in mice can be performed by the use of CD1d tetramers and in humans by using CD1d tetramers, a specific Vα24Jα18 Ab (clone 6B11) or the combination of anti-Vα24 and anti-Vβ11 antibodies. In contrast to conventional T cells which detect self or foreign peptide antigen–MHC complexes, iNKT cells recognize only glycolipid antigens bound to CD1d, a MHC class I-like glycoprotein (30). Currently, identified antigens are predominantly of non-mammalian nature, with α-galactosylceramide (α-GalCer) as the most potent and best studied example. However, also microbial derived (31) and endogenous ligands have been described (28, 32, 33). Of note, the human genome encodes five CD1d genes (CD1a, b, c, d, and e) whereas only CD1d is expressed in mice, and human CD1a, b, and c restricted T cells have been described too (34).

A hallmark of iNKT cell biology is the ability to secrete large amounts of cytokines and chemokines upon TCR recognition of lipid antigen–CD1 complexes or via indirect (TCR independent, mainly cytokine driven) stimulation, hereby acting as a “bridge” between innate and adaptive immune responses (35, 36). In analogy to classification of conventional T cells based on their cytokine production, iNKT cells can be subdivided in NKT1, NKT2, and NKT17 cells (37). Each of these subsets expresses distinct transcription factors which correlate with their capacity to secrete specific cytokines. NKT1 cells are T box transcription factor TBX21 (T-bet) positive and primarily secrete interferon (IFN)-γ, NKT2 cells express high levels of GATA-binding protein 3 (GATA3) and promyelocytic leukemia zinc finger protein (PLZF), and produce IL-4 and IL-13, and NKT17 cells express RORγt next to intermediate levels of PLZF and produce IL-17 as signature cytokine (38–40). All these subsets acquire their functional capacity during the development in the thymus and are distributed to the peripheral organs in a tissue-specific manner (41). However, there are also reports suggesting that peripheral iNKT cells are able to further functionally differentiate under inflammatory conditions (42, 43). In addition, it is also clear that iNKT cells experience further
maturation at mucosal surfaces (e.g., lung and gut) as evidenced from experiments with germ-free mice (44, 45).

Finally, next to above-mentioned subsets, also other particular iNKT cells, such as NKtα (FOXp3+) (46), NKtβ (CXCR5+ PD-1+) (47), NKT10 cells (48), and adipose tissue residing iNKT (PLZF-E4BP4+) cells (49) have been described and warrant further investigation. The frequency of iNKT cells in mice is substantially higher compared to humans. The majority of murine iNKT cells are found in the liver (20–40%), whereas iNKT cells constitute only 1% of cells in the human liver. Moreover, the iNKT cell frequencies in human peripheral blood samples shows significant inter-donor variation (approximately 0.01–0.5% of T cells) which makes the study of human iNKT cell biology more challenging.

Contribution to Gut and Joint Disease

Considering the ability of iNKT cells to produce copious amounts of immunomodulatory cytokines, several studies have assessed the capacity of iNKT cells to modulate autoimmune diseases (50–54). Some have shown that activation of iNKT cells can protect from joint inflammation, while others mentioned exacerbation of disease (2, 35, 52–58). In TNFΔARE/Δ mice, a TNF-driven SpA-like animal model for combined gut and joint inflammation, iNKT cells can dampen arthritis and joint inflammation, iNKT cells can be activated by TNF-driven CD1d+ CD8αα dendritic cells (DCs). Interestingly, the frequency of the latter cell population is increased in synovial fluid from SpA patients (52). This example, next to evidence from an iNKT cell-dependent infectious disease in vivo model, suggests that immunomodulatory DCs can pick up antigens from the microbiota or microbial-derived products at the intestinal draining sites and subsequently activate iNKT cells. Furthermore, the crosstalk between DCs and iNKT cells was found to be TNF-mediated (52, 59, 60). Collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA), two mouse models for RA, have revealed contradictive results. While several reports suggested a pathogenic role (55, 56, 61, 62), iNKT cells protected from disease in a number of studies (54, 63, 64). Conflicting outcomes could originate from differences in the stimulating ligand and the time point of iNKT cell activation, since these appeared to be crucial factors (54). Regarding human joint disease, it has been described that RA patients have lower frequencies of both CD4+ and CD4+ iNKT cells in peripheral blood compared to healthy controls, and they were skewed toward a Th1 phenotype (65–67) and a more restricted iNKT-TCR repertoire (68). There is no clear information regarding iNKT cell function in SpA disease so it will be of interest to study these, but also other innate-like T cells, in the context of joint–gut pathology in SpA patients.

Similar to joint disease, dichotomous effects of iNKT cells were observed for IBD (69). In dextran sodium sulfate-induced colitis, a model for human UC, activation of iNKT cells by α-GaCer ameliorated disease (70, 71). Adoptive transfer in iNKT deficient mice also had a protective role (70, 72, 73). In contrast, iNKT cells exacerbated inflammation in oxazolone-induced colitis, another UC model, as shown from results in CD1d and iNKT-deficient mice (74). Again it is clear that iNKT cells are involved in the pathogenesis, possibly even serving a dual role depending on the type of IBD (UC versus CD like) and the exact conditions of activation and further research is warranted to elucidate the mechanisms, ideally by using CD1d tetramer stainings. A large cohort of IBD patients showed that iNKT cells were decreased in the blood in both CD and UC compared to healthy individuals (75). The intestinal lamina propria of UC patients was found to have a strong abundance of type 2 iNKT cells that produced high amounts of the cytotoxic cytokine IL-13 (76, 77). Further studies are required to understand whether these disturbances in cell numbers in patients are a result of disease or whether iNKT cells are involved in development or persistence of inflammatory gut and joint disorders.

MAIT CELLS

Biology and Localization

Mucosal-associated invariant T cells are an evolutionarily highly conserved cell population with two defining traits: the expression of a semi-invariant TCR and restriction of recognizing antigens presented by the MHC class I-related molecule MR1. Similar to iNKT cells, their TCR consists of an invariant TCR α chain paired with a limited array of Vβ chains (Vo7.2αα33 paired with Vβ2 or Vβ13 in humans and Vo19Io33 paired with Vβ6 and Vβ8 chains in mice) (3). Also, MAIT cells can be stimulated by both TCR-activation and TCR-independent signals, such as IL-18 (36, 78). In both humans and mice, the majority of MAIT cells in peripheral blood and tissues are CD4+CD8αα+CD8αβ- (in particular, more CD8αα than CD8αβ), besides very few CD4-expressing cells (79). The development occurs in the thymus, followed by an extrathymically maturation, a process that is regulated by multiple factors, including MR1, commensal gut microbiota, and the transcription factor PLZF (80), as illustrated by their absence in MR1-deficient and germ-free mice (81) and their severely reduced frequency in PLZF-deficient mice (82).

Identifying MAIT cells in human blood and tissue can be based on expression of TCR Vo7.2 (TRA1-2) combined with the NK cell receptor CD161 and/or IL-18Rα (CD218). However, some of these surrogate markers are not present throughout the whole ontogeny, which has challenged accurately defining the cells. Recently, the production of MR1 tetramers meant a major revolution in this field, enabling the specific detection of MAIT cells in both humans and mice (82, 83). This has led to increased understanding of the development, which in mice occurs in three stages with only stage 3 being functionally competent. This model is largely in parallel with the development in humans (80). Furthermore, MR1 tetramers have allowed to describe different subsets within the MAIT cell population (84).

Mucosal-associated invariant T cells are predominantly found at mucosal and epithelial barrier sites. They are most abundant in the gastrointestinal tract and associated organs, such as mesenteric lymph nodes and the liver (in the latter organ representing 20–45% of all human T cells), but can also be found in the blood (1–8% of all human T cells). However, a lot of variation exists in the frequency of MAIT cells among humans, with age as an important determining factor (84). In mice, MAIT cells have a much lower frequency (at least 10-fold less than in humans) but are also mainly found at mucosal surfaces (82, 85). Because of their
localization in close contact with the microbiota, it is believed that MAIT cells serve an essential role in modulating host-microbial interplay (81). They recognize and can be activated by vitamin B2 (riboflavin) metabolites, such as ribityllumazines [for example, 5-OP-RU or 5-(2-oxopropylidamino)-6-D-ribitylaminouracil] and pyrimidines (80). As many vitamin biosynthetic pathways are restricted to bacteria and yeasts, it is believed that MAIT cells detect these antigens to respond toward microbial challenges.

The majority of MAIT cells (>80%) in peripheral blood of healthy humans was found to produce the Th1-related cytokines interferon-gamma (IFN-γ) and TNF (80). Only a small fraction could produce IL-17A, consistent with a low expression of RORγt in healthy subjects. However, it seems that peripheral expansion and maturation is particularly important in human MAIT cells, illustrated by a dominant IL-17A-producing MAIT cell population in the liver (86).

**Contribution to Gut and Joint Disease**

In contrast with their role as first-line responders against microbial infections (87), MAIT cells are also thought to be involved in a number of inflammatory and autoimmune disorders. In many of these diseases, a reduced systemic MAIT cell frequency compared with healthy individuals was observed, together with an increased abundance at sites where inflammation occurred (88, 89). For instance, IBD patients were found to have decreased peripheral blood MAIT cells with an enrichment in inflamed intestinal tissue (90, 91). In both RA (92) and AS (93, 94), there was a systemic decrease in MAIT cells accompanied by elevated cell numbers in the synovial fluid. It should be noted that in some of these diseases, like IBD and RA but not AS, results could be confounded by the use of corticosteroids as this has been associated with lower systemic MAIT cell frequencies (88). Furthermore, the identification in these studies was based on the expression of surrogate markers (TCRVα7.2+CD161hi) and not MR1-tetramer stainings. Upon activation, CD161 can be downregulated on MAIT cells, which could also have influenced these results (88).

Next to changes in frequencies, there were also phenotypical alterations in these diseases. In IBD, MAIT cells expressed higher levels of activation markers such as CD69 and they produced more IL-17 (90, 91). UC patients showed increased IL-18 serum levels and interestingly, a correlation was found with CD69 expression, suggesting that induced IL-18 secretion could have a role in activation of MAIT cells in these patients (91). The activation status of MAIT cells was positively correlated with disease activity of AS patients (94). An upregulation of IL-17 in these cells could also be observed in peripheral blood of AS patients compared to...
CONCLUSION

After believing for a long time that solely MHC–peptide complexes can be recognized by T cells, it is now known that TCRs can also bind (glyco)lipid, vitamin metabolites, and other non-peptidic antigens. These cell types include iNKT and MAIT cells, restricted to MHC class I-related molecules CD1d and MR1, respectively. Their evolutionary highly conserved nature indicates a strong selective pressure to be maintained in immune responses. Showing features of both the innate and adaptive immunity, these innate-like T cells act at the interface of the two systems. In this regard, it is not surprising that these cells, next to their distinct but still unclear resident role in liver tissue, are predominantly found at mucosal barriers, i.e., at sites where there is a close encounter with microorganisms. Next to direct activation by recognizing microbial-derived ligands via their semi-invariant TCR, they can also be activated indirectly (e.g., by cytokine and TLR-mediated signaling), upon which they respond by rapidly producing copious amounts of effector molecules as a first-line defense making them excellent gatekeepers against potential invasive pathogens (36, 97). However, innate-like T cells show a dichotomous phenotype, being not only protective but they are also thought to be involved in a number of immune and inflammatory diseases. Indeed, iNKT and MAIT cells might be skewed toward a predominant pro-inflammatory state in which secretion of key pathogenic cytokines such as IL-17 can cause tissue pathology (Figure 1) (26, 27). A pathological role for innate-like T cells is supported by evidence from diverse experimental models, although some conflicting results might reflect an aberrant role depending on the disease phenotype, activation kinetics, and the background of the animals (52, 57, 95). Interestingly, SpA-like gut and joint pathology shown in TNF- and IL-23-dependent animal models, such SKG and TNF$^{ARE}$ mice does not develop under germ-free conditions (98, 99). This underscores the relevance of the host (immune)-microbial interplay in the induction of SpA-like disease features. Additionally, a state of dysbiosis as discovered recently in SpA patients (10–12) might contribute to chronicity of disease by e.g., dysregulating immunomodulatory T cell function and cytokine (TNF and IL-17) mediated responses. Although one has to keep in mind that a causal relationship has not been proven yet, we would postulate that it takes "guts" to cause joint inflammation as observed in SpA pathology. However, many questions still need to be addressed. For example, a specific role for innate-like T cells in these microbiota-mediated pathological events clearly awaits further investigation, especially in light of the complexity of the human disease. Future in depth immunoprofiling of innate-like Tcells, next to other immunomodulatory cells, in gut and joint tissues from SpA patients, combined with further exploration of their function and role in experimental models under different microbial conditions (e.g., conventional versus germ-free housing), will shed additional light on the precise nature of the relationship between these unconventional cell populations and the microbiota, and their contribution to gut and joint diseases.

AUTHOR CONTRIBUTIONS

CM and SG contributed equally to this work. KV and DE shared supervision.

REFERENCES

1. Lanier LL. Shades of grey – the blurring view of innate and adaptive immunity. Nat Rev Immunol (2013) 13(2):73–4. doi:10.1038/nri3389
2. Venken K, Elewaout D. IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear. Curr Rheumatol Rep (2015) 17(5):30–8. doi:10.1007/s11926-015-0507-2
3. Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol (2014) 32:323–66. doi:10.1146/annurev-immunol-032713-120243
4. Kisielow J, Kopf M. The origin and fate of gammacdeltaT cell subsets. Curr Opin Immunol (2013) 25(2):181–8. doi:10.1016/j.coi.2013.03.002
5. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2011) 70(1):25–31. doi:10.1136/ard.2010.133645
6. Horta-Baas G, Romero-Figueroa MD, Montiel-Jarquin AJ, Pizano-Zarate ML, Garcia-Mena J, Ramirez-Duran N. Intestinal dysbiosis and rheumatoid arthritis: a link between gut microbiota and the pathogenesis of rheumatoid arthritis. J Immunol Res (2017) 2017:4835189. doi:10.1155/2017/4835189
7. Pedersen I, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 20(1):64–77. doi:10.3748/wjg.v20.i1.64
Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. *J Rheumatol* (1995) 22(12):2279–84.

De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthritis. *Gastroenterology* (1996) 110(6):1696–703. doi:10.1053/gast.1996.v110.pm9864393

Tito RY, Cyphers H, Joossens M, Varkas G, Van Praet L, Glorieus E, et al. Dialyzer as a microbial marker of disease activity in spondyloarthritis. *Arthritis Rheumatism* (2017) 69(9):114–21. doi:10.1002/art.39802

Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. *Ann Rheum Dis* (2017) 76(9):1614–22. doi:10.1136/annrheumdis-2016-211064

Stoll ML, Kumar R, Morrow CD, Letzkowski E, Cui XQ, Gienin A, et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. *Arthritis Res Ther* (2014) 16(4):486–96. doi:10.1186/s13075-014-0486-0

Moustafa A, Li WZ, Anderson EL, Wong EHM, Daluai PS, Sandborn WJ, et al. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. *Clin Transl Gastroenterol* (2018) 9:132–40. doi:10.1038/cctg.2017.58

Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. *Elife* (2013) 2:e01202. doi:10.7554/eLife.01202

Scher JU, Littman DR, Abramson SR. Microbiome in inflammatory arthritis and human rheumatic diseases. *Arthritis Rheumatol* (2016) 68(1):35–45. doi:10.1002/art.39259

Berthelot JM, Le Goff B. Rheumatoid arthritis and periodontal disease. *Rheum Dis Dial* (2007) 25:297–336. doi:10.1016/j.berh.2007.03.002

Chandra S, Kronenberg M. Activation and function of iNKT and MAIT cells. *Adv Immunol* (2015) 127:145–201. doi:10.1006/bs.ai.2015.03.003

Mikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, et al. The evolution of spondyloarthropathies in relation to gut histology. III. The clinical paradoxes. *Rheumatol* (2015) 43(1):76–82. doi:10.1093/rheumatology/keu113

Mikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. *J Rheumatol* (1995) 22(12):2279–84.

De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthritis. *Gastroenterology* (1996) 110(6):1696–703. doi:10.1053/gast.1996.v110.pm9864393
51. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. *Nat Med* (2003) 9(5):582–8. doi:10.1038/nm8531

52. Jacques P, Venken K, Van Beneden K, Hammad H, Seeuws S, Drennan MB, et al. Invariant natural killer T cells are natural regulators of murine spondyloarthritis. *Arthritis Rheum* (2010) 62(4):988–99. doi:10.1002/art.27324

53. Coppieters K, Dewint P, Van Beneden K, Jacques P, Seveuws S, Verbruggen G, et al. NKT cells: manipulable managers of joint inflammation. *Rheumatology* (2007) 46(4):565–71. doi:10.1093/rheumatology/kei437

54. Mortier et al. Innate-Like T Cells in Spondyloarthritis

55. Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH, et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta 1 production. *J Exp Med* (2005) 201(1):41–7. doi:10.1084/jem.20041400

56. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V(α)14 natural killer T cells in the pathogenesis of arthritis in murine models. *Arthritis Rheum* (2005) 52(6):1941–8. doi:10.1002/art.21056

57. Drennan MB, Aspelasgh S, Elewaut D. Invariant natural killer T cells in rheumatic disease: a joint dilemma. *Nat Rev Rheumatol* (2010) 6(2):90–8. doi:10.1038/nrrheum.2009.261

58. Elewaut D. Natural killer T cells and rheumatoid arthritis: friend or foe? *Arthritis Res Ther* (2005) 7(2):88–9. doi:10.1186/ar1714

59. Brígil M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. *Nat Immunol* (2003) 4(12):1230–7. doi:10.1038/ni1002

60. Skold M, Xiong XW, Illarionov PA, Besra GS, Behar SM. Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. *J Immunol* (2007) 179(4):2300–9. doi:10.4049/jimmunol.179.4.2300

61. Hornung M, Farkas SA, Sattler C, Schieltz HJ, Geissler EK. DX5(+)/NKT cells induce the death of colitis-associated cells: involvement of programmed death ligand-1. *Eur J Immunol* (2006) 36(5):1210–21. doi:10.1002/eji.200535332

62. Miellot A, Zhu R, Diem S, Boissier MC, Herbelin A, Bessis N. Activation of IL-13-producing NK-T cells. *J Immunol* (2002) 17(5):629–38. doi:10.4049/s1074-7613(02)00543-3

63. Grose RH, Thompson FM, Baxter AG, Pellicci DG, Cummins AG. Deficiency of invariant NKT cells in Crohn’s disease and ulcerative colitis. *Digest Dis Sci* (2007) 52(6):1415–22. doi:10.1002/dsd.9261-7

64. Ueno Y, Tanaka S, Sumii M, Miyake S, Tazuma S, Taniguchi M, et al. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of α/β natural killer T cells in mice. *Inflamm Bowel Dis* (2005) 11(1):35–41. doi:10.1017/S00054725-200510000-00005

65. Shibolet O, Kalish Y, Klein A, Alper R, Zolotar L, Thalenfeld B, et al. Adop- tive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis. *J Leukocyte Biol* (2004) 75(1):76–86. doi:10.1189/jlb.0703351

66. Reantragoon R, Boonpattanaporn N, Corbett AJ, McCluskey J. Mucosal-associated invariant T cells in clinical diseases. *Asian Pac J Allergy* (2016) 34(1):3–10.
90. Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. *Clin Exp Immunol* (2014) 176(2):266–74. doi:10.1111/cei.12277

91. Haga K, Chiba A, Shibuya T, Osada T, Ishikawa D, Kodani T, et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. *J Gastroen Hepatol* (2016) 31(5):965–72. doi:10.1111/igh.13242

92. Cho YN, Kee SJ, Kim TJ, Jin HM, Kim MJ, Jung HJ, et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. *J Immunol* (2014) 193(8):3891–901. doi:10.4049/jimmunol.1302701

93. Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. *Ann Rheum Dis* (2016) 75(12):2124–32. doi:10.1136/annrheumdis-2015-208902

94. Hayashi E, Chiba A, Tada K, Haga K, Kitagaichi M, Nakajima S, et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. *J Rheumatol* (2016) 43(9):1695–703. doi:10.3899/jrheum.151133

95. Chiba A, Tajima R, Tomi C, Miyazaki Y, Yamamura T, Miyake S. Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. *Arthritis Rheum* (2012) 64(1):153–61. doi:10.1002/art.33314

96. Ruijing X, Mengjun W, Xiaoling Z, Shu P, Mei W, Yingcheng Z, et al. Jα33+ MAIT cells play a protective role in TNBS induced intestinal inflammation. *Hepatogastroenterology* (2012) 59(113):762–7. doi:10.5755/hge.11432

97. Van Kaer L, Parekh VV, Wu L. The response of CD1d-restricted invariant NKT cells to microbial pathogens and their products. *Front Immunol* (2015) 6:226. doi:10.3389/fimmu.2015.00226

98. Rehaume LM, Mondot S, Aguirre de Carcer D, Velasco J, Benham H, Hasnain SZ, et al. ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. *Arthritis Rheumatol* (2014) 66(10):2780–92. doi:10.1002/art.38773

99. Schaubeck M, Clavel T, Calasan J, Lagkovardos I, Haange SB, Jehmlich N, et al. Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence. *Gut* (2016) 65(2):225–37. doi:10.1136/gutjnl-2015-309333

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.